STAT+: Pharmalittle: Lilly and Roche are also losers in the Medicare Alzheimer’s decision; former CRO owner pleads guilty to falsifying data

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of Pumpkin Spice for the occasion. Autumn, after all, is only eight months away. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So … here are some items of interest. Have a great day, everyone. …

Medicare may have released a plan to restrict access to the controversial Biogen (BIIB) Alzheimer’s drug, but the biggest losers may actually be other drug makers readying treatments for the debilitating disease, STAT explains. Both Eli Lilly (LLY) and Roche (RHHBY)…
Click here to view original post